Cecilia Brown

Associate Editor

Cecilia Brown is an Associate Editor for Blood Cancers Today.

Articles by Cecilia Brown

Cecilia BrownIndolent B-Cell Lymphoma | March 8, 2024
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Read More
Cecilia BrownPrint | January 3, 2024
Dr. Ghobrial discusses how she entered the field of smoldering myeloma, the racial gap in myeloma research, and more.
Cecilia BrownPrint | November 13, 2023
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
Cecilia BrownMyelodysplastic Syndromes | October 25, 2023
The study enrolled 214 participants, including 111 patients with 39 different RUNX1 variants from 45 unrelated families.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | February 8, 2024
Dr. Garcia-Manero said he hopes to find “better treatments” and even “one day a cure for this condition.”
Cecilia BrownMyelodysplastic Syndromes | October 24, 2023
Researchers found that 16% of the patients analyzed had pre-existing autoimmune disease.
Talha Badar, MBBS, MDMyelodysplastic Syndromes | October 23, 2023
Across the entire study population, the two most frequent U2AF1 variants were S34F (n=97) and Q157P (n=46).
Cecilia BrownMyeloma | October 16, 2023
The rate of grade 3-5 infections was 90% lower in MM patients receiving IV immunoglobulin than during the observation period.
Cecilia BrownIndolent B-Cell Lymphoma | October 13, 2023
Researchers used a classification approach derived from machine learning to stratify patients into two subgroups.
Cecilia BrownIndolent B-Cell Lymphoma | October 13, 2023
The combination was previously “found to be well tolerated with an early signal of efficacy in a phase Ib study.”
Cecilia BrownAggressive B-Cell Lymphoma | October 18, 2023
The subcutaneous T-cell engaging bispecific antibody is now approved for the treatment of this patient population in the EU.
Cecilia BrownAcute Myeloid Leukemia | October 11, 2023
The study included 815 patients with AML who were “unfit to receive intensive induction chemotherapy."
Cecilia BrownAcute Myeloid Leukemia | October 11, 2023
Mutations in IDH were “strongly correlated with increased age,” according to the study’s authors.
Cecilia BrownAcute Lymphoblastic Leukemia | October 3, 2023
The pooled ORR was 97% and the pooled complete remission rate was 93% in patients with ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | October 2, 2023
The study included 255 patients aged one to 30 years with low-risk first-relapse B-ALL.
Cecilia BrownChronic Myeloid Leukemia | October 11, 2023
Dr. Radich reflects on lessons in cowboy medicine, the genetics of luck, and a serendipitous meeting.
Cecilia BrownMeeting News | October 2, 2023
Researchers conducted a cross-sectional survey of patients with multiple myeloma to address the question.
Jorge Cortes, MDVideo Insights | September 29, 2023
The award was created in honor of Michael J. Keating, MD, a founding member and past president of SOHO.
Cecilia BrownMeeting News | September 28, 2023
Researchers evaluated 1,704 patients with triple-class exposure, including 1,072 who had four-plus previous lines of therapy.
Cecilia BrownMantle Cell Lymphoma | September 27, 2023
RNA sequencing analysis revealed noncanonical function of BACH1 in regulation of type I interferon response.